article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

It’s all part of a deep-seated commitment to innovation and its role as the company’s growth engine. Our pipeline, for example, includes a new class of recombinant antibodies. Right now, they are doing what is probably the most advanced work in the field of polyclonal recombinant antibody therapies.

Medicine 111
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

article thumbnail

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine.

Trials 40